Anti-Hemophilic Factor VIII Concentrate from Canada
A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Provide coagulation activity units per vial and viral safety dossiers
• Ensure lyophilized form with reconstitution instructions for stability
• Avoid bulk plasma classification by specifying patient-ready dosing